The ADC binds TROP2 on tumor cells and is internalized; a cleavable linker releases an exatecan-derived topoisomerase I inhibitor that blocks Topo I, causing DNA damage, cell-cycle arrest, and apoptosis. DNA topoisomerase I is the intracellular payload target, not the directly targeted antigen for cell killing.